HOME > TOP STORIES
TOP STORIES
-
BUSINESS Post-Azilva, Takeda Set to Morph into Rare Disease Specialty Pharma in Japan
April 20, 2022
-
REGULATORY SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
-
REGULATORY Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
-
REGULATORY Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
-
COMMENTARY Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
-
REGULATORY Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
April 18, 2022
-
BUSINESS Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
April 15, 2022
-
BUSINESS Lumakras Nears Japan Market, Amgen Eyes Simultaneous Launch with US for Next 5 Oncology Drugs: EVP
April 14, 2022
-
REGULATORY Chuikyo OKs Listing of 8 Drugs on April 20; Vyvgart, Lumakras, and More
April 13, 2022
-
REGULATORY Vyvgart, Pivlaz to Be 1st to Face Zero Premium Rule for Low Cost Disclosures
April 12, 2022
-
REGULATORY Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
-
BUSINESS Astellas, GSK, 2 Other Firms Log 10%-Plus Drop in Workforce: Jiho Poll
April 11, 2022
-
REGULATORY MHLW Set to Boost Recognition of Reporting System for Improper Drug Promotions
April 8, 2022
-
BUSINESS New Grad Hiring Down 4.4% in Spring 2022, Downtrend for Sales Reps Continues: Poll
April 7, 2022
-
BUSINESS Jardiance Now Allowed for Use in HFpEF Patients: Label Update
April 7, 2022
-
BUSINESS Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
-
BUSINESS Pfizer Tops 2021 Global Pharma Ranking on Vaccine Boon: Jiho Tally
April 6, 2022
-
REGULATORY SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
-
ORGANIZATION JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
-
REGULATORY Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
